Doxorubicin in experimental and clinical heart failure.
Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties. Prevention strategies have not demonstrated the expected success and unfortunately, this specific type of heart failure does not respond to the usual medical therapy as other kinds of heart failure. Therefore, surgical procedures may be necessary in some patients. Cardiac transplantation is performed in most cases but it requires the cure of the neoplastic disease. This usually requires a recurrence-free interval of several years which is associated with a high attrition rate in these patients due to their cardiac disease. Therefore, other conservative and surgical treatment concepts were developed during the last years. This review presents the most common procedures and discusses their efficacy as well as their clinical applicability.
Christiansen
Stefan
S
Department of Cardiothoracic Surgery, University of Aachen, Pauwelsstr. 30, 52074 Aachen, Germany. schristiansen@ukaachen.de
Autschbach
Rüdiger
R
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D004285:Dogs; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006333:Heart Failure / Q000139:chemically induced* / Q000517:prevention & control / Q000601:surgery; D016027:Heart Transplantation; D006801:Humans; D023421:Models, Animal; D009369:Neoplasms / Q000188:drug therapy; D013552:Swine
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin